drugset
drugset / Trial / NCT03377023

Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer

NCT03377023 ↗

Phase 1/2 Active not recruiting 66 enrolled H. Lee Moffitt Cancer Center and Research Institute
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The main purpose of this study is to see if the combination of nivolumab, ipilimumab and nintedanib is effective in people with non- small cell lung cancer. Researchers also want to find out if the combination of nivolumab, ipilimumab and nintedanib is safe and tolerable.

Timeline

Start
2018-02-02
Primary completion
2023-11-28
Completion
2026-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Ipilimumab Monoclonal antibody 1 mg/kg Intravenous
Subject Nintedanib Small molecule 100 mg Oral
Subject Nintedanib Small molecule 150 mg Oral
Subject Nintedanib Small molecule 200 mg Oral
Subject Nivolumab Monoclonal antibody 3 mg/kg Intravenous

Indications

non-small cell lung carcinoma